Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B. Pope, Xin Qiao, Hyun J. Kim et al. · Journal of Neuro-Oncology · 2012
Cited by 160 works. doi:10.1007/s11060-012-0847-y
Authors
- Whitney B. Pope
- Xin Qiao
- Albert Lai
- Phioanh Leia Nghiemphu
- Benjamin M. Ellingson
- David Schiff
- Dawit Gebremichael Aregawi
- Soonmee Cha
- Vinay K. Puduvalli
- Jing Wu
- Wai-Kwan Alfred Yung
- Geoffrey S. Young
- James J. Vredenburgh
- Daniel P. Barboriak
- Lauren E. Abrey
- Tom Mikkelsen
- Rajan Jain
- Nina A. Paleologos
References
- Response criteria for phase II studies of supratentorial malignant glioma.
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
- Bevacizumab for recurrent malignant gliomas
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- Pseudoprogression and pseudoresponse in the treatment of gliomas
- Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment